



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Sugemalimab

Cat. No.:	HY-P99114
CAS No.:	2256084-03-2
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research ^[1] .
IC₅₀ & Target	PD-L1 ^[1]
In Vitro	Sugemalimab (CS1001) specifically binds to PD-L1, competitively blocks the binding of human PD-L1 with PD-1 and CD80, and effectively induces CD4+ T lymphocyte proliferation and enhances the production of interferon- γ and interleukin-2 ^[2] . Sugemalimab employs IgG4 isotype and lacks antibody-dependent cellular mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Sugemalimab (CS1001) significantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model ^[2] . Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Dhillon S, et al. Sugemalimab: First Approval. *Drugs*. 2022 Apr;82(5):593-599.

[2]. Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. *Cancer Research*, 2020, 80(16_Supplement): 3260-3260.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA